<DOC>
	<DOCNO>NCT02081768</DOCNO>
	<brief_summary>There consensus literature best way treat cystic lesion pituitary area . Patients symptomatic tumour rare . The cystic form tumour present special challenge since traditional treatment modality ( surgery and/or external radiation ) often able completely remove treat cyst wall without major morbidity even mortality . There 'best practice ' treatment cystic tumour per se . Treatments available patient cystic sellar/parasellar tumour include conservative management use 'wait scan ' approach , cyst drainage , cyst removal via transsphenoidal and/or craniotomy approach ( i.e . open surgery ) . Over last 10 year treat approximately 8 patient intracystic radiotherapy . All patient continue monitor clinically radiologically do well stable regression cysts new neurological deficit . Over past 2 year , 90yttrium colloid provide CDHA Health Canada 's Special Access Program ( SAP ) . It recent Health Canada request clinical trial ass benefit intracystic radiotherapy available treatment option . The experimental treatment propose stereotactic intracavitary instillation 90yttrium colloid treatment cystic lesion pituitary ( sellar ) surround area ( parasellar ) .</brief_summary>
	<brief_title>90Yttrium Colloid Treatment Cystic Sellar/Parasellar Tumors</brief_title>
	<detailed_description />
	<criteria>Criteria Ages Eligible Study : 17 year age old Genders Eligible Study : Both Accepts Healthy Volunteers : No Inclusion Criteria Patients meet follow criterion eligible enrollment study participant : 1 . Patients 17 year age old . 2 . Cystic sellar , suprasellar , parasellar intrasellar mass diagnose histology , cytology neuroimaging . 3 . Tumour measurement and/or tumour volume calculate . 4 . Patients require surgical intervention determine treat neurosurgeon . 5 . Being patient manage Halifax Neuropituitary Program surgical clinic . 6 . Willingness undergo surgery give inform surgical consent . 7 . Willingness provide inform consent study participation . Exclusion Criteria Patients meet criterion eligible enrollment study participant : 1 . Neurosurgeon 's assessment surgical procedure hold unacceptable operative risk . 2 . Having solid tumour . 3 . Pregnant breast feeding time surgical consent and/or surgery . 4 . Hypersensitivity , allergies contraindication use radiopharmaceutical agent ( 90yttrium colloid ) .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Rathke 's cleft cyst</keyword>
	<keyword>cystic craniopharyngiomas</keyword>
</DOC>